|
|
|
| BioPlan Associates is conducting its 23rd Annual Global Biopharmaceutical Manufacturing and Trends Analysis and needs your insights for the biopharma industry’s most comprehensive global benchmarking analysis! For over 20 years, BioPlan Associates has analyzed advances in bioprocessing, new technologies, and emerging trends, supported by global institutional and media partners. For all completed, qualified surveys, they'll offer an Amazon e-gift card, a copy of the summary results, and the 2026 Top Trends in Biomanufacturing White Paper. |
|
|
|
|
|
|
By Cell & Gene The Podcast | In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the development of and FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). | |
|
|
|
|
| Developing Community-Based And Trial-Naïve Sites: The Real ROI | Article | By Catherine Jervis, MRN - Medical Research Network | Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment. |
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
| Connect With Cell & Gene: |
|
|
|
